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 A BSTRACT 
 The current informal practice of pharmacometrics as a com-
bination art and science makes it hard to appreciate the role 
that informatics can and should play in the future of the dis-
cipline and to comprehend the gaps that exist because of its 
absence. The development of pharmacometric informatics 
has important implications for expediting decision making 
and for improving the reliability of decisions made in model-
based development. We argue that well-defi ned informatics 
for pharmacometrics can lead to much needed improvements 
in the effi ciency, effectiveness, and reliability of the pharma-
cometrics process. 
 The purpose of this paper is to provide a description of the 
pervasive yet often poorly appreciated role of informatics in 
improving the process of data assembly, a critical task in the 
delivery of pharmacometric analysis results. First, we pro-
vide a brief description of the pharmacometric analysis pro-
cess. Second, we describe the business processes required 
to create analysis-ready data sets for the pharmacometri-
cian. Third, we describe selected informatic elements 
required to support the pharmacometrics and data assembly 
processes. Finally, we offer specifi c suggestions for per-
forming a systematic analysis of existing challenges as an 
approach to defi ning the next generation of pharmacometric 
informatics. 
 K EYWORDS:  Pharmacometrics ,  informatics ,  ontology ,  sys-
tematics 
 AN UNCOMMON VIGNETTE — PART 1 
 The CEO of a pharmaceutical company, tired of late-stage 
development failures and Food and Drug Administration 
(FDA) questioning regarding dose selection, decides to act 
on the promise of pharmacometrics.  “ Fix it, ” he says to the 
head of clinical pharmacology,  “ I don ’ t care what it takes! ” 
The clinical pharmacologist agrees to take on the challenge 
and asks for a data programmer and pharmacometrician. 
Seizing on an opportunity to spearhead an upcoming  “ end 
of phase 2 ” meeting with the FDA, the pharmacologist 
quickly sketches out his strategy for the modeling activities 
required for dose selection and justifi cation. He then 
instructs his programmer to assemble the required data set 
using the data from several phase 1 studies and a recently 
completed phase 2 study. A week later he discovers that the 
modeling has not begun because the data set is still not 
ready.  “ What is taking so long? ” he wonders. 
 INTRODUCTION 
 We are at the beginning of a profound shift in the strategies 
used for designing drug development programs and secur-
ing regulatory approval. This shift comes amid recognition 
of the declining productivity of the pharmaceutical and bio-
technology industry, the rising costs of research and devel-
opment activities, concerns about the human and fi nancial 
implications of late-stage failures of development programs, 
and the societal implications of the rising costs of new med-
icines. 1 Each of these concerns, and the corresponding soci-
etal, political, and industrial responses, will have signifi cant 
implications for the vitality of the pharmaceutical industry. 
This in turn will affect our ability to capitalize on new 
advances in biomedical knowledge and to develop innova-
tions in diagnostic tools, therapeutic interventions, and pre-
ventative treatments. 
 These concerns have prompted an evaluation of the strengths 
and limitations of the development paradigm that currently 
dominates industry and regulatory decision making, a para-
digm primarily based on empirical clinical trials. One con-
sequence of this evaluation has been the consideration of 
model-based development as an alternative strategy for 
assessing the safety and effectiveness of new medicines. 
Model-based development uses the sciences of pharmaco-
kinetics, pharmacodynamics, and statistics to create mathe-
matical equations to create representations ( “ models ” ) of 
the putative links between treatments and observed effects. 
These drug-disease models, also referred to as pharmaco-
metric or quantitative pharmacology models, combine 
knowledge of a disease state, relevant biomarkers, and fi rst 
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principles of drug effects from preclinical and early clinical 
studies with knowledge of placebo response and drop-out 
rates to gain insight into the determinants of effi cacy and 
safety outcomes. 2 This model-based strategy differs from 
the existing paradigm in that empirical evidence of effi cacy 
will no longer be suffi cient; the study design, the informa-
tion collected in clinical trials, and the interpretation of 
results will be guided by a quantitative model based in turn 
on a scientifi c theory of why such effi cacy outcomes are 
observed. 
 If this evolution to model-based development continues to 
unfold, then quantitative models and the information bases 
on which they rest will play an increasingly dominant role. 
The models will become the principal instruments for the 
design and evaluation of clinical trials and will be consid-
ered to be among the major deliverables of drug develop-
ment programs. In this context, the models become critical 
to drug development and regulatory decision making as 
well as the foundation for attempts to ensure the safe and 
effective use of medicines in clinical applications. A suc-
cessful transition to model-based development, will require 
that modeling and simulation results are reliably available 
at key decision-making milestones, and that these results 
are capable of supporting the decision-making process at a 
hitherto diffi cult to achieve level of sophistication. This will 
require in turn that current, critical obstacles to coherent data 
management, particularly the lack of well-defi ned informat-
ics, be addressed. 
 WHAT IS INFORMATICS? 
 Informatics in the Oxford English Dictionary, ninth edition, 
is defi ned as  “ the study of the structure, behavior, and inter-
actions of natural and artifi cial computational systems. ” It 
encompasses the study of systems that represent, process, 
and communicate information, including computational, 
cognitive, and social aspects, and of the associated informa-
tion objects themselves and of their relations to entities 
in reality. The central notion is that of the transformation of 
information. In this sense, informatics can be considered as 
encompassing computer science, cognitive science, artifi cial 
intelligence, information science, and a variety of domain-
specifi c fi elds. 
 This broad defi nition supports our expectation of an ever 
more pervasive role for informatics in a knowledge-generating 
enterprise such as drug development. We are convinced that 
informatics will rapidly be recognized as a critical determi-
nant of effectiveness and productivity, although it is not yet 
recognized as such by many of the stakeholders involved in the 
pharmacometrics process. 3 
 In a manufacturing environment, informatics is information 
about the  parts used in the manufacturing process to assem-
ble a product, including the steps in this manufacturing pro-
cess itself. The informatics in manufacturing encompass the 
product defi nitions that convert technical needs and com-
plex requirements defi nitions into complete prescriptive 
system descriptions. 4 The product development process 
then converts these product defi nitions into build pack-
ages to create systems capable of delivering the desired 
product. 5 Informatics has an utterly pervasive role in the 
processes required to provision, execute, and govern a 
manufacturing enterprise. In fact, the effi ciency and effec-
tiveness of a manufacturing enterprise is directly related 
to completeness, fi delity, and computational availability of 
product defi nitions. 6 
 In the pharmacometrics environment, informatics repre-
sents information about the drug concentration-time 
data, covariates, and outcome data used for exposure-
response analyses. Informatics here includes also the 
metadata associated with the information in a database, 
analysis requirements, specifications for data assembly, 
information about the process of modeling and simulation 
such as measures of acceptability, and the information used 
for guiding the content and format of the presentation of 
results.  Table 1 shows the tasks involved in the pharma-
cometric analysis process as it is currently executed, 
lists selected examples of the informatic elements 
required, and describes the implications of well-defined 
informatics. 
 THE PHARMACOMETRIC ANALYSIS PROCESS 
 Pharmacometric analysis is invoked by the formulation of 
queries to address gaps in knowledge of the determinants of 
drug effects. 9 Its principal inputs are target product profi les 
defi ning pharmacological and pharmacoeconomic base-
lines, designs and protocols for clinical trials aimed at dem-
onstrating safety and effi cacy in subject populations, and 
prior knowledge in the form of information bases and tech-
nical literature. The principal outputs of pharmacometric 
analysis typically include characterizations of drug kinetics, 
drug dynamics, including characterizations of various phar-
macological measures of safety and effi cacy end points, and 
simulations yielding predictions of outcomes under various 
scenarios of interest. The pharmacometrics modeling and 
simulation process that has evolved to meet the current 
needs of drug development teams typically encompasses 
the 7 major tasks of analysis planning, data assembly, 
exploratory analysis, modeling, simulation, model valida-
tion, and presentation of results. 9 
 Of these tasks, the assembly of analysis-ready data set for 
pharmacometric analysis stands out in terms of the require-
ments for detailed informatics that goes beyond what is cur-
rently available. Data acquisition and management tasks 
required for the preparation of pharmacometric analysis-ready 
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data sets have always been a challenge. Unlike traditional 
statistical analysis, in which the focus is on the data from a 
single study, pharmacometric analyses often involve data 
arising from multiple sources during various phases of drug 
development. Comprehensive pharmacokinetic data from 
healthy volunteers in early phase I studies are typically used 
for the development of an initial pharmacokinetic model. 
These data are then combined with sparse pharmacokinetic 
samples collected in subjects enrolled in early phase II 
dose-ranging studies in order to expand the scope of the 
pharmacokinetic model and explore sources of variability in 
exposure. 10 This pharmacokinetic model may then be com-
bined with a pharmacodynamic model in order to assess the 
impact of pharmacodynamic variability and other factors 
on patient outcome. It is not uncommon for data from mul-
tiple phase II and III clinical trials to be combined for an 
exposure-response analysis, particularly in support of 
regulatory decision making. 11 
 In addition to the complexities associated with pooling of 
data from different studies and phases of development, the 
creation of pharmacometric analysis data sets has been 
further burdened by the current ad hoc implementation of 
pharmacometric analyses within the traditional drug devel-
opment paradigm. If a population pharmacokinetic evalua-
tion is considered at the time of study design and protocol 
development, it is at best a secondary or tertiary objective of 
the trial, which is mainly designed to support the primary 
Table 1. Selected Examples of Informatic Elements Illustrating Their Pervasive Role in Pharmacometric Analysis
Analysis Task
Selected Informatic 
Elements Implications of Well-Defi ned Informatics
Analysis planning Analysis requirements, MOA, 
 prior knowledge, target 
 product profi les
Improved communications between the pharmacometrician and the 
 development team; 
 reduced ambiguity in outsourcing specifi cations
Data assembly Informatic and logistic 
 requirements
Locating data, assessing information content of a data set to determine 
 suitability for analysis, programming instructions for preparing 
 analysis-ready data sets
Exploratory 
 analysis
Taxonomy of pharmacometric 
 entities and relationships
Basis for automated and standardized code and displays; reduced time 




Analysis plans, MOA, 
 archiving schema
A basis for standardizing data and facilitating data pooling across studies 
 and programs; 
 a basis for implementing CDISC requirements with 
 enhancements to specifi cally address pharmacometrics needs and 
 other data-driven activities, such as adaptive trial design; ability to 
 use knowledge gained across development programs; ability to 
 compare and select models based on suitability for purpose
Validation MOA, scientifi c standards, 
 regulatory requirements
Process modifi cation and upgrade defi nitions
Presentation XML tags, style sheets7 Development of canonical documents that serve as a driver of quality 
 and reliability8
CDISC indicates Clinical Data Interchange Standards Consortium; MOA, measures of acceptability; XML, Extensible Markup Language.
effi cacy and safety analyses. As such, design considerations, 
including sampling times for pharmacokinetic measure-
ments, data collection forms, and study timelines, including 
decision-making milestones, are often in place long before 
pharmacometric modeling activities are considered and 
these analyses must be retrofi tted to accomplish as much as 
possible given these other immovable constraints. As a result, 
pharmacometric analysis plans, if developed, are based on 
strategies to make the best of what is available rather than 
prospectively planned to maximize the value of the effort. 
 AN UNCOMMON VIGNETTE — PART 2 
 Before too long the pharmacologist realizes that his ability 
to drive the  “ end of the phase 2 ” meeting agenda is in seri-
ous jeopardy.  “ I only had 1 hour to come up with the analy-
sis plan, ” he complains to the pharmacometrician.  “ I thought 
that you knew how these datasets are usually constructed. ” 
Then, turning to the data programmer he complains,  “ It ’ s 
only concentration data from a couple of trials. The statisti-
cians are already done with their analysis. ” The pharmaco-
metrician and data programmer cast knowing looks at one 
another and begin to detail the fi rst round of issues they 
have already faced. 
 “ After we defi ned the population to be included and spent 
half a day explaining to the statisticians how we would rec-
oncile the differences between our population and theirs, we 
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realized that neither the exact dates and times of dosing nor 
blood sampling were ever cleaned, and as a result about 
50% of the previous doses looked like they were taken after 
the blood sample was collected instead of before. Once we 
addressed that issue, we realized that there was no unique 
identifi er on the sample requisition form for one of the stud-
ies, so unless we can come up with a strategy that produces 
something reasonable, we ’ ll have to exclude the whole 
study. You mentioned that we ’ d need a variable to indicate 
fed/fasted status because there is an effect of food on phar-
macokinetics. In the Phase 1 studies, this can be easily 
defi ned; in Phase 2, we can make assumptions based on the 
protocol; but in Phase 3, it ’ s anyone ’ s guess, so you ’ ll have 
to let us know how to assign it. For the effi cacy end point, 
we can easily fi nd the calculated change from baseline last 
observation carried forward measure, but you want all of 
the interim measurements on the raw scale, right? And we 
haven ’ t even considered how to handle missing creatinine 
clearance values yet! Should we go on? ” 
 THE DATA ASSEMBLY PROCESS FOR 
PHARMACOMETRIC ANALYSIS 
 The creation of an analysis-ready data set consists of pre-
paring a time-ordered sequence of relevant pharmacokinetic 
and pharmacodynamic events for each subject from the 
series of studies that have been selected for inclusion in the 
data set for analysis. Selecting the data for inclusion in the 
analysis, deciding on the structure and content of the analy-
sis-ready data set, and setting the strategy for pharmaco-
metric analysis requires a clear and concise statement of the 
requirements for the analysis. These requirements, includ-
ing the pharmacokinetic and pharmacodynamic models to 
be used for the analysis, the subject population, and so forth, 
are incorporated into an analysis plan and subsequently 
translated into data programming specifi cations. These 
specifi cations are developed on the basis of several sources, 
including previous study results, the experience of the team 
members involved, data availability, and written documen-
tation, the latter including, but not limited to, the investiga-
tor ’ s brochure, protocols, clinical study reports, and data 
collection forms. The work orders for the data programmers 
specify the key analysis variables, including requirements 
for the preparation of analysis-ready data sets, along with 
specifi cations for graphical and tabular displays for the ini-
tial exploratory data analyses. 
 Figure 1 depicts the core tasks required to create an analysis-
ready data set for the pharmacometrician. In response to a 
query for pharmacometric analysis, data are requested and 
received, reviewed and converted from raw data to infor-
mation based on analysis requirements, reassembled and 
tested for effectiveness, and ultimately delivered for use in 
the pharmacometric analysis. 
 Once programming begins, starting with receipt of data and 
continuing through its validation, there are inevitably ques-
tions that arise and require discussion, resolution, and poten-
tial re-creation of the data set. The programmer is likely to 
identify a host of issues that may cause problems or result in 
inconsistencies in the analysis data set. Often, the program-
mer will identify an invalid data item or data that are missing. 
The programmer may have diffi culty defi ning an integrated 
dosing history. When multiple studies are pooled, it is often 
the case that derived variables are not consistent across the 
protocols. It is not uncommon for patient information to 
have been recorded accurately, but critical data might still 
be unavailable or unusable because of patient protocol 
noncompliance. 
 These issues may spawn a series of meetings and e-mail 
exchanges between the various members of the project 
team, particularly the pharmacometrician and the data pro-
grammer, but such exchanges might also need to include the 
members of the clinical team responsible for the drug devel-
opment program, the program statisticians, and senior man-
agement. During the course of these conversations, a series 
of algorithms and rules to be used for the creation of the 
data set is developed. These rules require consideration of 
what has already been created or coded by upstream data 
management processes. Modifi cations are made to the anal-
ysis creation programs based on the new algorithms and 
rules. We can thereby think of the data assembly process as 
 Figure 1.  Process for creating an analysis-ready data set for 
pharmacometrics. Each subtask involves inputs (requirements), 
deliverables (tangible proof of completion of subprocess), and 
outputs (strategy/information for next subprocess). 
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an onion — once one set (or layer) of issues is unraveled, it is 
often the case that a fresh, more complex layer is exposed. 
Additional rounds of e-mails and meetings are required for 
the resolution of each layer of issues. Identifi cation and res-
olution of these issues can result in lengthy delays in the 
completion of the data programming activities. It is not 
uncommon for data assembly activities to require a third of 
the total time for completion of an analysis. Add to this 
the urgency for completion of the data assembly task — the 
data-fi tting tasks cannot begin until the data are available —
 coupled with the frustration for all team members when 
the data assembly process must be repeated to address 
inadvertent omissions in the statement of requirements and 
the importance of comprehensively defi ning analysis require-
ments before the start of data assembly becomes apparent. 
This is true even with the presence of experienced program-
mers who may fi nd it diffi cult to solicit the necessary infor-
mation from scientists unable or unwilling to cooperate 
because of time, experience, or worldview constraints. 
 Eventually, an analysis data set will be completed. Explor-
atory graphical displays are created and reviewed to ensure 
that the data set requirements were satisfi ed. This review 
will inevitably yield questions about outliers and odd values 
(with respect to demographic characteristics, time/date 
issues, concentration values interpreted as abnormal in rela-
tionship to the time of dosing, and so forth). Additional edits 
based on results of the exploratory graphical displays will 
be performed, resulting in the fi nal analysis-ready data set. 
And when once the latter is built, a quality assurance pro-
cess is conducted on the data set so that a fi nal analysis-
ready version can be documented and released for use in the 
pharmacometric analysis. 
 THE INFORMATIC NEEDS OF PHARMACOMETRIC 
DATA ASSEMBLY 
 The 2 parts of the vignette presented above dramatize a real 
and growing problem for pharmacometricians and data-
programming staff in committing to the reliable and timely 
delivery of results for decision-making purposes. These 
activities require heretofore-unavailable types of product 
defi nition data; that is, they require the informatics to spe-
cifi cally support the data assembly process at all levels and 
from the very start. 
 Table 2 contains selected examples of the types of infor-
matics elements required to properly support the data 
assembly process for pharmacometric analysis if the tran-
sition to model-based development is to be successful. 
This list is nonexhaustive and the informatics elements are 
not mutually exclusive, so that similar information might 
be obtained from different sources. The vague nature of 
some of these elements refl ects the fact that the importance, 
uses, and sources of these elements are just beginning to be 
appreciated and documented, and the issue of shared, set-
tled, and coherent standards is only just beginning to be 
addressed. 
 In recent years, there has been considerable effort to improve 
the informatics available for the drug development process. 
One such effort is the Clinical Data Interchange Standards 
Consortium (CDISC), an open, multidisciplinary, nonprofi t 
organization, whose goal is to establish industry standards to 
support the electronic acquisition, exchange, submission, 
and archiving of clinical trial data and metadata for  medical 
and biopharmaceutical product development. 12 Although 
this has been a signifi cant effort, it is unclear whether this 
initiative will address the specialized needs of pharmacomet-
ric analysis. In large measure, the initiatives that have been 
taken have focused on standardizing vocabulary, formats, 
and submission specifi cations of clinical trial data, specifi -
cally from the perspective of traditional statistical analysis 
and database design, such as hypothesis testing on change 
from baseline and last observation carried forward data. 
 Analysis data sets for traditional intent-to-treat analyses are 
typically constructed for a specifi c analysis purpose, eg, for 
the primary effi cacy and safety analyses. In traditional ana-
lyses, dose exposure in the analysis data set is imprecise and 
based on generalized assumptions, eg, patients were treated 
with 200 mg once a day for 28 days. In contrast, pharmaco-
metric analyses require that data from numerous domains be 
combined into one time-ordered data set. Dosing informa-
tion, times of drug concentration measurements, meal infor-
mation, demographic characteristics, laboratory results, and 
concomitant medication data must be combined, and to this 
end all of them must be formulated using standard vocabu-
lary and classifi cations. Importantly, precise date and time 
information is required for all events. For these reasons, it is 
not surprising that the current Study Data Tabulation Model 
(SDTM) domain models do not cover the production of anal-
ysis data sets for population pharmacokinetic analysis. 13 
 DEFINING THE NEXT GENERATION 
PHARMACOMETRICS INFORMATICS 
 During the process of data assembly and data set creation as 
illustrated in  Figure 1 , the pharmacometrician and data pro-
grammer focus on 3 questions. What are the requirements 
of the analysis? What data are needed to perform an analy-
sis that will meet these requirements? What data are actu-
ally available for inclusion in the analysis? The challenge of 
answering these questions is compounded by the fact that 
the process must for several important reasons be iterative. 
This is to take account of the fact that the requirements for 
an analysis will likely change over time, the development 
team or regulatory agency may raise new questions, new 
fi ndings and understandings may emerge, and new data may 
become available as the development program matures. 
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 In the process of developing answers to these questions, a 
series of further, and more specifi c, questions are formulated 
as the pharmacometrician and data programmer go back and 
forth to clarify issues and resolve uncertainties. This cycle of 
questioning, assessment, and discussion inherent in the cur-
rent manual — and largely experiential — process is a valu-
able source of information about the fundamental entities 
and relationships invoked by pharmacometric analysis, and 
can be used as input for standardization efforts in the future. 
 Figure 2 illustrates how a systematic analysis can be super-
imposed on existing pharmacometrics processes in such a 
way as to improve the delivery of modeling and simulation 
results to the development programs of the future. The chal-
lenges in performing these modeling and simulation activi-
ties, including data set assembly, can yield a rich catalog of 
the problems currently faced by the pharmacometrics team. 
Such a catalog could be created by examining the written 
materials generated during the course of data assembly and 
analysis (including e-mail between members of the team 
attempting to clarify issues; changes in workscopes and 
analysis plans that occur during the course of an analysis; 
fi nal deliverables such as technical reports and presenta-
tions; and minutes of team meetings dealing with data 
assembly issues). We believe that the formal, systematic 
analysis of these materials, coupled with a critical consider-
ation of the CDISC and other standards would yield a valu-
able resource providing an overview of the types of entities 
and relations involved in the domain of pharmacometric 
analysis that could provide a basis to improve the perfor-
mance of data assembly, provide needed insight into future 
CDISC improvements for pharmacometrics, and create 
functional specifi cations for future software applications to 
facilitate pharmacometric analysis. 
 ONTOLOGY FOR PHARMACOMETRICS 
 Ontology as a branch of philosophy is the science of the 
kinds and structures of objects, properties, events, processes, 
Table 2. Selected Examples of Informatic Elements Required to Support Data Assembly for Pharmacometric Analysis
Source Informatic Elements Examples
Analysis plans Defi nition of what is to be modeled and how it will be 
 modeled, covariates to be assessed, and so forth
Strategy for dealing with metabolite 
 concentrations as a covariate in the analysis 
 or as a dependent variable for the 
 pharmacokinetic structural model
Study design Planned execution strategy and intent of clinical trials Inclusion and exclusion criteria, strategy for 
 defi ning evaluable populations for modeling 
 and simulation activities
Pharmacokinetic 
 sampling strategy
Timing and frequency of blood sampling, dosing details, 
 and so forth
Sparse sampling, eg, “peak” and “trough” 
 samples vs random sampling, or intensive 
 full-profi le sampling; dosing regimen, eg, 
 single dose or multiple dosing
Metadata Format and structure of data elements Format for time variable, eg, clock time 
 HHMMSS vs duration (1.5 hours)
Code list Information for mapping to a standardized terminology Concomitant medicines for drug-drug 
 interaction analysis specifi ed as specifi c 
 generic name vs member of a therapeutic 




Submission and archiving standards Content for defi ne. XML, change control 
 procedures
Data pooling Information required for pooling data from multiple sources Standardized laboratory data collected at 
 various laboratory locations for multiple 
 trials, information for reconciling 
 inconsistent codelist values across studies, 
 eg, yes/no, 1/0, and so forth
“Secret sources” Implicit information that must be gleaned from data-collection 
 forms, protocols, visualization of database content rather 
 than from explicit sources
Information on how data were intended to be 
 collected, eg, time intervals for collection of 
 urine volumes are specifi ed on the data-
 collection form but not in protocol or 
 database
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and relations. 14 Ontology seeks to provide a classifi cation 
of these entities and relation that is, relative to a given set of 
purposes, defi nitive and exhaustive. The classifi cation 
should be defi nitive in the sense that it can serve as an 
answer to such questions as: What classes of entities are 
needed for a description and explanation of the goings on in 
a given domain? It should be exhaustive in the sense that all 
relevant types of entities should be included in the classifi -
cation, including also the types of relations by which enti-
ties are tied together to form larger wholes. And it should as 
far as possible refl ect a consensus-based standardization, so 
that the requirements of multiple suppliers and users of data 
can be met. 
 These ontologies are in many ways comparable to the tax-
onomies produced by sciences such as biology or chemis-
try, although they are more general than these. Ontologists 
study the totality of those objects, properties, processes, and 
relations that make up the world on different levels of focus 
and granularity, and whose different parts and moments are 
studied by the different scientifi c disciplines. Ontology, in 
the sense that is relevant for our purposes here is a descrip-
tive enterprise. It seeks taxonomy and description rather 
than predication and explanation. 
 In recent years, the term  “ ontology ” has come to be applied 
in the fi eld of computer and information science. The big 
task for the new ontology derives from what we might call 
the Tower of Babel problem. Different groups of data- and 
 Figure 2.  Systematic analysis of pharmacometric challenges as a 
basis for developing a pharmacometrics ontology and refi ned 
informatics, processes, and requirements defi nition. 
knowledge-based system designers have their own idiosyn-
cratic terms and concepts by means of which they build 
frameworks for information representation. Different data-
bases may use identical labels but with different meanings; 
alternatively, the same meaning may be expressed via dif-
ferent names. As ever more diverse groups are involved in 
sharing and translating ever more diverse varieties of infor-
mation, the problems standing in the way of putting this 
information together within a single system increase geo-
metrically. The term  “ ontology ” has come to be used by 
information scientists to refer to shared controlled vocabu-
laries for referring to entities in given domains and for 
capturing the relations between them in algorithmically 
tractable ways. An ontology in this context is a dictionary of 
terms formulated in a canonical syntax and with commonly 
accepted defi nitions designed to yield a lexical or taxonomi-
cal framework for knowledge representation that can be 
shared by different information systems and communities. 
Already a variety of efforts are under way to advance the 
quality of ontologies used to support data management and 
reasoning in the biomedical domain. We believe that high-
quality ontologies devised for the needs of pharmacomet-
rics can provide the necessary coordination of informatic 
elements in a robust framework that will allow not only 
enhanced retrieval and quality assurance of data but also 
reasoning with these data in ways that are scheduled to 
become increasingly indispensable. 
 AN UNCOMMON VIGNETTE — EPILOGUE 
 “ Currently, ” the clinical pharmacologist might conclude, 
 “ it ’ s a gamble as to whether any modeling and simulation 
effort can successfully meet the timelines for a major pro-
gram deliverable. Every project is different. We do the best 
we can with what we have. ” The consequence is that too 
often submission deadlines are met by means of a quick-
and-dirty pulling together of graphics and text cut and pasted 
from previous reports in order to create a story for the dose 
selection and justifi cation briefi ng book. Although pharma-
cometricians recognize that this quick-and-dirty approach is 
not the best, they are sometimes forced to rationalize the 
effort over the impossibility of the task. This has the devel-
opment team wondering when and if they will ever under-
stand what pharmacometrics really has to offer. 
 SUMMARY 
 Under current conditions, any attempt to elicit the infor-
matic needs of a pharmacometric analysis from pharmaco-
metricians or data managers will undoubtedly result in an 
extensive list of complex and varied reasons why the assem-
bly of an analysis-ready data set can take such a long time. 
The intuitive and informal approach typically used to 
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address these problems and improve the effi cient and effec-
tive preparation of analysis-ready data sets is inadequate for 
anything more than a cursory analysis and the development 
of temporary fi xes. Unfortunately, these temporary fi xes 
generally result in other unintended problems that might 
then be the subject of another round of cursory analysis. 
Ontology is designed to provide a solution precisely for this 
problem — to turn what is an art into a science. 
 The current informal practice of pharmacometrics as com-
bination art and science makes it hard to appreciate the role 
that robust ontology-based informatics should play and the 
gap that exists because of its absence. The development of 
pharmacometric informatics has important implications for 
expediting decision making and improving the reliability of 
these decisions in drug development. Well-defi ned ontolo-
gies can create an informatics that is tailored for pharmaco-
metrics in a way that can enable needed improvements in 
the effi ciency, effectiveness, and reliability of the pharma-
cometrics process. For example, a clear understanding of 
informatic elements would enable the development of a 
comprehensive list of questions to be addressed at the begin-
ning of a project. This information would improve under-
standing of the relevant entities and relationships for an 
analysis and improve communications between the pharma-
cometrician and the development team by reducing ambigu-
ity and catching errors, inconsistencies, and gaps in analysis 
plans and data-programming specifi cations. This, in turn, 
would reduce the time required to assess the information 
content of a data set, allow proofreading of data sets by 
checking their conformity with the ontology, improve the 
accuracy of the assessment, and reduce the time required to 
prepare an analysis-ready data set from multiple sources of 
data. Informatics would facilitate the creation of automated 
and standardized code and displays that reduce the time 
required to respond to regulatory requests for data and 
analyses. Informatics are also key to developing an under-
standing of the modifi cations required to upstream and 
downstream processes, including the development of train-
ing programs, if real improvements are to be realized. 
 If the results of pharmacometric analyses are to be for-
mally incorporated into the fabric of decision making dur-
ing drug development, we will need comprehensive and 
defi nitive informatics based on a controlled, structured 
vocabulary. This vocabulary is essential if we are to effi -
ciently and effectively generate pharmacometric results as 
well as judge the adequacy and relevance of the results in 
decision making. 
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